Skip to main content

Advertisement

SpringerLink
Log in

Therapeutic options in advanced prostate cancer: Present and future

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Patients with advanced prostate cancer now have many treatment options available including first-and second-line hormonal therapy, radiotherapy, bisphosphonate therapy with zoledronic acid, and taxane-based chemotherapy. These options now give clinicians an opportunity to offer their patients symptomatic relief and most importantly improve overall survival. This article reviews the current treatment options available for men with advanced prostate cancer. In addition, novel treatment options under development, including calcitriol, immunotherapies, small molecule inhibitors, and nucleotide-based targeted therapy, are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993, 71(Suppl):1098–1109.

    Article  PubMed  CAS  Google Scholar 

  2. Tannock IF, de Wit R, Berry WR, et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502–1512.

    Article  PubMed  CAS  Google Scholar 

  3. Petrylak DP, Tangen CM, Hussain MH, et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513–1520.

    Article  PubMed  CAS  Google Scholar 

  4. Klotz L: Combined androgen blockade: an update. Urol Clin North Am 2006, 33:161–166.

    Article  PubMed  Google Scholar 

  5. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists’ Collaborative Group. Lancet 2000, 355:1491–1498.

    Article  Google Scholar 

  6. Chaudhary UB, Rashid MH, Onitilo AA, Bissada NK: Secondary horm onal manipulations in the management of advanced prostate cancer. Can J Urol 2005, 12:2666–2676.

    PubMed  Google Scholar 

  7. Taylor CD, Elson P, Trump DL: Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993, 11:2167–2172.

    PubMed  CAS  Google Scholar 

  8. Crook J: Radiation therapy and radio-nuclides for palliation of bone pain. Urol Clin North Am 2006, 33:219–226.

    Article  PubMed  Google Scholar 

  9. Lee MV, Fong EM, Singer ER, Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001, 61:2602–2608.

    PubMed  CAS  Google Scholar 

  10. Saad F, Gleason DM, Murray R, et al.: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96:879–882.

    Article  PubMed  CAS  Google Scholar 

  11. Smith MR, Eastham J, Gleason DM, et al.: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008–2012.

    Article  PubMed  CAS  Google Scholar 

  12. Beer TM, Myrthue A: Calcitriol in the treatment of prostate cancer. Anticancer Res 2006, 26:2647–2651.

    PubMed  CAS  Google Scholar 

  13. Beer TM: ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU Int 2005, 96:508–513.

    Article  PubMed  CAS  Google Scholar 

  14. Small EJ, Schellhammer PF, Higano CS, et al.: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic horm one refractory prostate cancer. J Clin Oncol 2006, 24:3089–3094.

    Article  PubMed  CAS  Google Scholar 

  15. Simons J, Higano C, Corman J: A phase I/II trial of high dose allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic horm one-refractory prostate cancer [abstract 667]. Proc Am Soc Clin Oncol 2003, 22:166.

    Google Scholar 

  16. Small E, Higano C, Smith D: A phase 2 study of an allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic horm one-refractory prostate cancer (HRPC). Proceedings of the ASCO Annual Meeting 2004. Alexandria: J Clin Oncol 2004; 22(Suppl 145):2505.

    Google Scholar 

  17. Dipaola R, Plante M, Kaufman H, et al.: A phase I trial of pox PSA vaccines (PROSTVAC(R)-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOMtrademark) in patients with prostate cancer. J Transl Med 2006, 4:1.

    Article  PubMed  CAS  Google Scholar 

  18. Picus J, Halabi B, Rini N, et al.: The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: Initial results of CALGB 90006 [abstract 1578]. Proc Am Soc Clin Oncol 2003, 22.

  19. Oh WK, Halabi S, WK Kelly, et al.: A phase II study of estramustine, docetaxel and carboplatin (EDC) with G-CSF support in men with horm one refractory prostate cancer (HRPC): CALGB 9813 [abstract 779]. Proc Am Soc Clin Oncol 2002, 21.

  20. Small EJ, Reese DM, Um B, et al.: Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999, 5:1738–1744.

    PubMed  CAS  Google Scholar 

  21. Rini BI, Weinberg V, Bok R, et al.: Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol 2003, 21:99–105.

    Article  PubMed  CAS  Google Scholar 

  22. Nelson J, Bagnato A, Battistini B, Nisen P: The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003, 3:110–116.

    Article  PubMed  CAS  Google Scholar 

  23. Carducci MA, Padley RJ, Breul J, et al.: Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003, 21:679–689.

    Article  PubMed  CAS  Google Scholar 

  24. Carducci MA, Nelson JB, Saad F: Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: Phase 3 study [abstract 4508]. J Clin Oncol 2004, 22(Suppl 14).

  25. Vogelzang NJ, Nelson JB, Schulman CC, et al.: Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer. Proceedings of the Prostate Cancer Symposium 2005. Alexandria: ASCO 2005; Abstract 269.

    Google Scholar 

  26. Lin AM, Rini BI, Weinberg V, et al.: A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int 2006, 98:763–769.

    Article  PubMed  CAS  Google Scholar 

  27. Mathew P, Fidler IJ, Logothetis CJ: Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Semin Oncol 2004, 31(2 Suppl 6):24–29.

    Article  PubMed  CAS  Google Scholar 

  28. Gleave ME, Monia BP: Antisense therapy for cancer. Nat Rev Cancer 2005, 5:468–479.

    Article  PubMed  CAS  Google Scholar 

  29. Steinberg J, Oyasu R, Lang S, et al.: Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 1997, 3:1707–1711.

    PubMed  CAS  Google Scholar 

  30. July LV, Akbari M, Zellweger T, et al.: Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002, 50:179–188.

    Article  PubMed  CAS  Google Scholar 

  31. Miyake H, Nelson C, Rennie PS, Gleave ME: Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000, 60:170–176.

    PubMed  CAS  Google Scholar 

  32. Miyake H, Chi KN, Gleave ME: Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2000, 6:1655–1663.

    PubMed  CAS  Google Scholar 

  33. Zellweger T, Chi K, Miyake H, et al.: Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 2002, 8:3276–3284.

    PubMed  CAS  Google Scholar 

  34. Zellweger T, Miyake H, Cooper S, et al.: Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther 2001, 298:934–940.

    PubMed  CAS  Google Scholar 

  35. Chi KN, Eisenhauer E, Fazli L, et al.: A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005, 97:1287–1296.

    Article  PubMed  CAS  Google Scholar 

  36. Chi KN, Eisenhauer E, Siu L, et al.: A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCIC CTG IND. Proceedings of the ASCO Annual Meeting 2005. Alexandria: J Clin Oncol 2005, 23: 3085. Abstract 153.

    Google Scholar 

  37. Jaattela M: Escaping cell death: survival proteins in cancer. Exp Cell Res 1999, 248:30–43.

    Article  PubMed  CAS  Google Scholar 

  38. Eder IE, Hoffmann J, Rogatsch H, et al.: Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther 2002, 9:117–125.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Prostate Centre at Vancouver General Hospital, 2775 Laurel Street, Level 6, Vancouver, BC, V5Z1M9, Canada

    Martin E. Gleave MD

Authors
  1. Richard D. Sowery MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan I. So MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin E. Gleave MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin E. Gleave MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sowery, R.D., So, A.I. & Gleave, M.E. Therapeutic options in advanced prostate cancer: Present and future. Curr Urol Rep 8, 53–59 (2007). https://doi.org/10.1007/s11934-007-0021-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-007-0021-9

Keywords

Search

Navigation